TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07809607: An Open-Label, Multicenter, Phase I Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YF087 in Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficie

Sponsor: InventisBio Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07809607 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07809607 Rescue Dossier →